These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 21820554)
1. Vaccine development against Trypanosoma cruzi and Chagas disease. Vázquez-Chagoyán JC; Gupta S; Garg NJ Adv Parasitol; 2011; 75():121-46. PubMed ID: 21820554 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671 [TBL] [Abstract][Full Text] [Related]
3. Current status and future prospects for a vaccine against American trypanosomiasis. Garg N; Bhatia V Expert Rev Vaccines; 2005 Dec; 4(6):867-80. PubMed ID: 16372882 [TBL] [Abstract][Full Text] [Related]
4. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080 [TBL] [Abstract][Full Text] [Related]
5. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466 [TBL] [Abstract][Full Text] [Related]
10. Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine. Miyahira Y Parasitol Int; 2008 Mar; 57(1):38-48. PubMed ID: 17728174 [TBL] [Abstract][Full Text] [Related]
12. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Limon-Flores AY; Cervera-Cetina R; Tzec-Arjona JL; Ek-Macias L; Sánchez-Burgos G; Ramirez-Sierra MJ; Cruz-Chan JV; VanWynsberghe NR; Dumonteil E Vaccine; 2010 Oct; 28(46):7414-9. PubMed ID: 20850536 [TBL] [Abstract][Full Text] [Related]
13. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Dumonteil E Infect Genet Evol; 2009 Dec; 9(6):1075-82. PubMed ID: 19805015 [TBL] [Abstract][Full Text] [Related]
14. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction? Basso B; Marini V Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810 [TBL] [Abstract][Full Text] [Related]
15. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease]. Braun M; de Titto E Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884 [TBL] [Abstract][Full Text] [Related]
16. Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Vasconcelos JR; Hiyane MI; Marinho CR; Claser C; Machado AM; Gazzinelli RT; Bruña-Romero O; Alvarez JM; Boscardin SB; Rodrigues MM Hum Gene Ther; 2004 Sep; 15(9):878-86. PubMed ID: 15353042 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of immune responses raised against Tc13 antigens of Trypanosoma cruzi in the outcome of murine experimental infection. García GA; Arnaiz MR; Esteva MI; Laucella SA; Garavaglia PA; Ibarra SE; Ruiz AM Parasitology; 2008 Mar; 135(3):347-57. PubMed ID: 17991305 [TBL] [Abstract][Full Text] [Related]
19. From genome screening to creation of vaccine against Trypanosoma cruzi by use of immunoinformatics. Teh-Poot C; Tzec-Arjona E; Martínez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Dumonteil E J Infect Dis; 2015 Jan; 211(2):258-66. PubMed ID: 25070943 [TBL] [Abstract][Full Text] [Related]
20. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]